51 RESULTS
CONFERENCE COVERAGE 2020-03-05 Conference Coverage Tau2020, the first of what may become a regular “pan-tau” conference (see Part 1 of this series), got off to a brisk start February 12–13 in Washington, D.C. Researchers who focus on primary tauopathies, such as progressive supranuclea
CONFERENCE COVERAGE 2020-03-06 Conference Coverage Scientists studying the non-Alzheimer’s disease tauopathies have struggled to find tracers that will bind the particular forms of tau that predominate in those diseases. At Tau2020, held February 12–13 in Washington, D.C., Gil Rabinovi
CONFERENCE COVERAGE 2020-03-07 Conference Coverage Evidence now seems overwhelming that toxic forms of tau spread from cell to cell, causing the characteristic progression of tauopathies such as Alzheimer’s and frontotemporal dementia. But how does tau get from one cell to another? At
RESEARCH NEWS 2020-03-10 Research News A new antibody turbocharges TREM2, the most ardent supporter of microglia. In mice, that is. According to a study published March 10 in the EMBO Journal, a monoclonal antibody trained against the mouse microglial receptor prevents shedding o
COMMUNITY NEWS 2020-03-12 Community News More than 5 million Americans currently live with Alzheimer’s disease, and that number will likely triple by 2050, according to the Alzheimer’s Association’s annual Facts and Figures report, released March 11. The deluge of cases could over
COMMUNITY NEWS 2020-03-24 Community News While science groups worldwide are grappling with the logistics of shutting down to comply with the social distancing required to slow the spread of COVID-19, neurodegenerative disease researchers are asking how they can help. And help they
COMMUNITY NEWS 2020-03-28 Community News As the COVID-19 pandemic engulfs the globe, it puts extraordinary strain on at-risk groups—very much including people with neurodegenerative disease and their carers. Not only do most people with neurodegenerative diseases fall into the age
RESEARCH NEWS 2020-03-31 Research News Researchers stunned the field last summer when they reported that phosphorylated tau turns up in peoples’ plasma decades before they show signs of dementia. The data bore the promise of a blood test for early Alzheimer’s disease—one that is
RESEARCH NEWS 2020-04-01 Research News An aspirin a day does not keep dementia away. Nor does it hedge the risk of mild cognitive impairment or slow decline, according to results published March 25 in Neurology. Reasoning that the anti-inflammatory and cardiovascular health benef
CONFERENCE COVERAGE 2020-04-03 Conference Coverage The conference may be virtual, but the data is real. At the online AAT-ADPD 2020, researchers presented their talks and posters in much that same way as they would have in person—albeit without the open question-and-answer time. Up tod
CONFERENCE COVERAGE 2020-04-10 Conference Coverage At the virtual AAT-AD/PD Focus meeting held April 1 to 5, clinicians and funders involved in the Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU) fired up their home computers to discuss results from the first DIAN-TU tre
CONFERENCE COVERAGE 2020-04-15 Conference Coverage Because cognition in Alzheimer’s disease declines as tangles spread, and tau research tools are finally in hand, researchers are increasingly homing in on tau immunotherapy. At the second biannual Advances in Alzheimer’s and Parkinson’
CONFERENCE COVERAGE 2020-04-16 Conference Coverage At the virtual AAT-AD/PD meeting, held April 2 to 5 online, researchers substantiated some prior hints on potential causal connections between the throngs of bacteria inhabiting the gut, how microglia function in the brain, and deposit
CONFERENCE COVERAGE 2020-04-22 Conference Coverage At the second biannual Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting (AAT-AD/PD), held virtually April 2 to 5, companies offered some news on investigational Parkinson’s therapies in Phase 1. One approach is targeted
CONFERENCE COVERAGE 2020-04-22 Conference Coverage Certain variants in the TREM2 gene more than triple a person’s risk of AD, seemingly by sapping the protective function this microglial receptor performs. According to findings presented at the virtual AAT-AD/PD meeting, held April 2 t
